<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201311015987N8</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2014-08-05</date_registration>
      <primary_sponsor>Tehran University of Medical  Science</primary_sponsor>
      <public_title>The Effect of Oat Cream on skin reaction caused by radiotherapy.</public_title>
      <acronym></acronym>
      <scientific_title>The assessment of Avena Sativa cream efficacy on skin reactions caused by radiotherapy in patients  with breast cancer.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2014-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/6452</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Breast Cancer.</hc_freetext>
      <i_freetext>Intervention 1: At the first time of beginning radiotherapy we will recommend to patients use the cream which prepared from oat extract, three times a day each 8 hours daily (TDS),  in the radiotherapy area, amount of one finger (FTU) will be applied uniformly with the index finger ( considerably in different patients based on the extent of the lesion, this unit can be doubled) and for 3 hours, they must avoid washing the area. Intervention 2: In the control group patients will use placebo (extract-free cream base).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Shahrzad ghiyasvandiyan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Nursing &amp; Midwifery, Tohid square</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 6642 0739</telephone>
        <email>shghiyas@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences,School of Nursing and Midwifery</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Shahrzad ghiyasvandian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Nursing &amp; Midwifery, Tohid square</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733171</zip>
        <telephone>+98 21 6642 0739</telephone>
        <email>shghiyas@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Science/School of Nursing and Midwifery</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: Women with breast cancer; Without any skin lesion.&#13;
Exclusion criteria: Patients with uncontrolled diabetes; Acquired immunodeficiency syndrome; A history of allergy to medicinal plants.</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>C50.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Malignant Neoplasm of Breast</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>At the first time of beginning radiotherapy we will recommend to patients use the cream which prepared from oat extract, three times a day each 8 hours daily (TDS),  in the radiotherapy area, amount of one finger (FTU) will be applied uniformly with the index finger ( considerably in different patients based on the extent of the lesion, this unit can be doubled) and for 3 hours, they must avoid washing the area.</i_keyword>
      <i_keyword>In the control group patients will use placebo (extract-free cream base).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The grade of skin reaction caused by radioytherapy. Timepoint: At the intervals of 10 days after initiation of treatment , 28 days after initiation of treatment, on the last day of radiotherapy and  after that in two times with one week interval, after the end of radiotherapy participants will be followed up. Method of measurement: Using the RTOG questionnaire and researcher-made questionnaire.</prim_outcome>
      <prim_outcome>Erythema. Timepoint: At the intervals of 10 days after initiation of treatment , 28 days after initiation of treatment, on the last day of radiotherapy and  after that in two times with one week interval, after the end of radiotherapy participants will be followed up. Method of measurement: Using the RTOG questionnaire and researcher-made questionnaire.</prim_outcome>
      <prim_outcome>Dry desquamation. Timepoint: At the intervals of 10 days after initiation of treatment , 28 days after initiation of treatment, on the last day of radiotherapy and  after that in two times with one week interval, after the end of radiotherapy participants will be followed up. Method of measurement: Using the RTOG questionnaire and researcher-made questionnaire.</prim_outcome>
      <prim_outcome>Itching. Timepoint: At the intervals of 10 days after initiation of treatment , 28 days after initiation of treatment, on the last day of radiotherapy and  after that in two times with one week interval, after the end of radiotherapy participants will be followed up. Method of measurement: Ask the patient and using a researcher-made questionnaire.</prim_outcome>
      <prim_outcome>Burning sensation. Timepoint: At the intervals of 10 days after initiation of treatment , 28 days after initiation of treatment, on the last day of radiotherapy and  after that in two times with one week interval, after the end of radiotherapy participants will be followed up. Method of measurement: Ask the patient and using a researcher-made questionnaire.</prim_outcome>
      <prim_outcome>Changes in daily activities. Timepoint: At the intervals of 10 days after initiation of treatment , 28 days after initiation of treatment, on the last day of radiotherapy and  after that in two times with one week interval, after the end of radiotherapy participants will be followed up. Method of measurement: Ask the patient.</prim_outcome>
      <prim_outcome>Tenderness. Timepoint: At the intervals of 10 days after initiation of treatment , 28 days after initiation of treatment, on the last day of radiotherapy and  after that in two times with one week interval, after the end of radiotherapy participants will be followed up. Method of measurement: Ask the patient.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Patchy and Distribution  Moist Desquamation. Timepoint: At the intervals of 10 days after initiation of treatment , 28 days after initiation of treatment, on the last day of radiotherapy and  after that in two times with one week interval, after the end of radiotherapy participants will be followed up. Method of measurement: Examination by a physician.</sec_outcome>
      <sec_outcome>Drainage, Infection, Cellulitis. Timepoint: At the intervals of 10 days after initiation of treatment , 28 days after initiation of treatment, on the last day of radiotherapy and  after that in two times with one week interval, after the end of radiotherapy participants will be followed up. Method of measurement: Examination by a physician.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical  Science</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2014-05-19</approval_date>
        <contact_name>Research Deputy Tehran University of Medical Sciences</contact_name>
        <contact_address>sixth floor of the University Center, Qods St, Keshavarz Blvd.  Tel: 88987382 - Fax: 88989664 Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
